Author: admin

MELAS Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “MELAS Syndrome Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MELAS Syndrome pipeline landscape. It covers the MELAS Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the MELAS Syndrome Treatment Landscape @ MELAS Syndrome Pipeline Outlook

Key Takeaways from the MELAS Syndrome Pipeline Report

  • In June 2025, Tisento Therapeutics announced a PRIZM study is evaluating 2 dose levels of zagociguat in a crossover design consisting of two 12-week treatment periods separated by a 4-week washout. Patients will be screened and if eligible, randomly assigned either to receive placebo in period 1 followed by active drug in period 2 OR to receive active drug in period 1 followed by placebo in period 2. Study medication is a once daily oral tablet and will be provided at the clinic and/or shipped to the participant’s home. Clinic visits will occur at screening and Week 1 and Week 12 of each treatment period.
  • In May 2025, Thiogenesis Therapeutics Inc. announced a Study Exit visit will occur at Week 24, and subjects will be offered to continue on an open-label extension study of TTI-0102. If a subject does not complete the study, they will be asked to return for a Study Exit visit 4 weeks after last study drug dose.
  • DelveInsight’s MELAS Syndrome pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for MELAS Syndrome treatment.
  • The leading MELAS Syndrome Companies such as Cyclerion Therapeutics Inc., Khondrion BV, Abliva AB and others.
  • Promising MELAS Syndrome Therapies such as TTI-0102, Idebenone, zagociguat 15mg, KH176, Vatiquinone, OMT-28 and others.

Discover groundbreaking developments in MELAS Syndrome Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ MELAS Syndrome Clinical Trials Assessment

MELAS Syndrome Emerging Drugs Profile

  • Sonlicromanol: Khondrion

Sonlicromanol is Khondrion’s lead investigational drug, developed as a first-in-class, brain-penetrant redox modulator with anti-inflammatory properties. It is designed to treat primary mitochondrial diseases (PMD) by targeting disrupted cellular redox balance and mitochondrial dysfunction. The drug modulates reactive oxygen species (ROS) levels and supports mitochondrial function by influencing key metabolic and inflammatory signaling pathways, potentially modifying disease progression rather than just alleviating symptoms. Currently, the drug is in Phase III stage of its clinical trial for the treatment of MELAS Syndrome.

  • CY-6463: Cyclerion Therapeutics

CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. In the CNS, the NO-sGC-cGMP pathway regulates diverse and critical biological functions including neuronal function, neuroinflammation, cellular bioenergetics, and vascular dynamics. Although it has been successfully targeted with several drugs in the periphery, this mechanism has yet to be fully leveraged therapeutically in the CNS, where impaired NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of many neurodegenerative and neuropsychiatric diseases and other disorders associated with cognitive impairment. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. Currently, the drug is in Phase II stage of its clinical trial for the treatment of MELAS Syndrome.

The MELAS Syndrome Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of MELAS Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for MELAS Syndrome Treatment.
  • MELAS Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • MELAS Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the MELAS Syndrome market

Stay informed about the MELAS Syndrome pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ MELAS Syndrome Unmet Needs

MELAS Syndrome Companies

Cyclerion Therapeutics Inc., Khondrion BV, Abliva AB and others.

MELAS Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

MELAS Syndrome Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Transform your understanding of the MELAS Syndrome Pipeline! See the latest progress in drug development and clinical research @ MELAS Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the MELAS Syndrome Pipeline Report

  • Coverage- Global
  • MELAS Syndrome Companies- Cyclerion Therapeutics Inc., Khondrion BV, Abliva AB and others.
  • MELAS Syndrome Therapies- TTI-0102, Idebenone, zagociguat 15mg, KH176, Vatiquinone, OMT-28 and others.
  • MELAS Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • MELAS Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Genetic Disorders Research–Access the Full MELAS Syndrome Pipeline Analysis Today! @ MELAS Syndrome Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. MELAS Syndrome : Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. MELAS Syndrome – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sonlicromanol: Khondrion
  9. Mid Stage Products (Phase II)
  10. CY-6463: Cyclerion Therapeutics
  11. Early Stage Products (Phase I)
  12. Drug Name: Company Name
  13. Preclinical Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. MELAS Syndrome – Collaborations Assessment- Licensing / Partnering / Funding
  17. MELAS Syndrome – Unmet Needs
  18. MELAS Syndrome – Market Drivers and Barriers
  19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/melas-syndrome-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MELAS Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Cystic Fibrosis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Cystic fibrosis Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Cystic Fibrosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Cystic Fibrosis Pipeline Outlook Report

Key Takeaways from the Cystic Fibrosis Pipeline Report

  • In July 2025, Enterprise Therapeutics Ltd conducted a study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared.
  • In July 2025, Boehringer Ingelheim announced a study is for people with cystic fibrosis who took part in a previous study with a medicine called BI 3720931. The main purpose of this study is to monitor the long-term health of participants who were treated with BI 3720931 in the previous study. Participants in this study do not receive additional treatment with BI 3720931.
  • DelveInsight’s Cystic Fibrosis pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Cystic Fibrosis treatment.
  • The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others.
  • Promising Cystic fibrosis Pipeline Therapies such as Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others.

Discover how the Cystic Fibrosis treatment paradigm is evolving. Access DelveInsight’s in-depth Cystic Fibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Cystic Fibrosis Clinical Trials and Studies

Cystic Fibrosis Emerging Drugs Profile

  • AP-PA02: Armata Pharmaceuticals

AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an emphasis on patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). Phages that comprise AP-PA02 were selected with desired attributes for a product candidate targeting P. aeruginosa lung infections. AP-PA02 is comprised of a cocktail of natural P. aeruginosa phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility and cooperativity, and further characterized by being highly potent and having a broad host range. Currently, the drug is in the Phase II stage of its development for the treatment of Cystic Fibrosis.

  • VX-522: Vertex Pharmaceuticals

VX-522 is an investigational messenger ribonucleic acid (mRNA) therapy aims to address the underlying cause of cystic fibrosis (CF). It is being evaluated by Vertex to treat lung disease for people living with CF who cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatments because they do not make any CFTR protein that responds to a CFTR modulator therapy. VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle. Once delivered to the target lung cells, the mRNA is designed to produce functional copies of the CFTR protein. VX-522 is the result of an exclusive research collaboration established with Moderna in 2016. Currently the drug is in Phase I/II stage of its development for the treatment of Cystic fibrosis.

  • KB407: Krystal Biotech

KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of CF by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered via a nebulizer. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation. Currently the drug is in Phase I stage of its development for the treatment of Cystic fibrosis.

  • SPL23: SpliSense

The CF W1282X mutation generates a Premature Termination Codon (PTC), leading to RNA degradation induced by the Nonsense Mediated RNA Decay (NMD) mechanism. W1282X does not respond to CFTR modulator drugs. Heterozygous patients carrying the F508del mutation and a minimal function mutation are responsive to Vertex triple combination therapy (Trikafta®). Significantly, around 50% of CF patients carrying W1282X also carry a non-F508del mutation on the second allele. For those patients, no effective treatment is available. SPL23 ASO given by inhalation, penetrates the cells and induces skipping over exon 23 in the CFTR transcript. Skipping exon 23 bypasses the NMD leading to mature and active CFTR. The activity of these CFTR channels can be further augmented by CFTR modulators. Currently the drug is in Preclinical stage of its development for the treatment of Cystic fibrosis.

The Cystic Fibrosis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
  • Cystic Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market

Explore groundbreaking therapies and clinical trials in the Cystic Fibrosis Pipeline. Access DelveInsight’s detailed report now! @ New Cystic Fibrosis Drugs

Cystic Fibrosis Companies

Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others.

Cystic fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Cystic Fibrosis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Cystic Fibrosis Pipeline Report

  • Coverage- Global
  • Cystic Fibrosis Companies- Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others.
  • Cystic fibrosis Pipeline Therapies- Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others.
  • Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Cystic Fibrosis drug development? Find out in DelveInsight’s exclusive Cystic Fibrosis Pipeline Report—access it now! @ Cystic Fibrosis Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Cystic Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cystic Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. AP-PA02: Armata Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. VX-522: Vertex Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SPL23: SpliSense
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cystic Fibrosis -Key Companies
  21. Cystic Fibrosis -Key Products
  22. Cystic Fibrosis – Unmet Needs
  23. Cystic Fibrosis – Market Drivers and Barriers
  24. Cystic Fibrosis – Future Perspectives and Conclusion
  25. Cystic Fibrosis -Analyst Views
  26. Cystic Fibrosis- Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystic Fibrosis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Metastatic Merkel Cell Carcinoma Pipeline Insight 2025: Immunotherapies, Targeted Agents, and Novel Biologics Reshape the Treatment Landscape | DelveInsight

“Metastatic Merkel Cell Carcinoma Pipeline”
The therapeutic pipeline for metastatic Merkel cell carcinoma is advancing rapidly, driven by the urgent need for durable treatments in this rare and aggressive neuroendocrine skin cancer. Immune checkpoint inhibitors targeting PD-1/PD-L1 have transformed care, providing lasting responses for some patients. However, resistance, relapse, and limited efficacy in certain cases underscore ongoing unmet needs.

DelveInsight’s “Metastatic Merkel Cell Carcinoma – Pipeline Insight, 2025” highlights an expanding portfolio of investigational therapies spanning immunotherapies, targeted agents, and next-generation biologics. Novel immune checkpoint modulators, including LAG-3, TIGIT, and CTLA-4 inhibitors, are being studied in combination strategies to overcome resistance and boost response rates. Oncolytic viruses, cancer vaccines, and T-cell–based therapies are advancing in clinical stages, aiming to enhance tumor-specific immune activation. In parallel, precision-targeted agents such as PI3K/AKT/mTOR inhibitors, epigenetic modulators, and antibody-drug conjugates are under evaluation to address molecular vulnerabilities in MCC tumors.

The 2025 mMCC pipeline reflects a paradigm shift toward combination regimens and biomarker-driven innovation, aiming to expand survival benefits and overcome current therapeutic limitations. Backed by regulatory incentives for rare cancers, increasing clinical collaborations, and rising investment in immuno-oncology, the future landscape of metastatic Merkel cell carcinoma holds promise for more durable, personalized, and accessible treatment pathways.

Interested in learning more about the current treatment landscape and the key drivers shaping the metastatic Merkel cell carcinoma pipeline? Click here

 

Key Takeaways from the Metastatic Merkel Cell Carcinoma Pipeline Report

• DelveInsight’s metastatic Merkel cell carcinoma pipeline analysis depicts a strong space with 13+ active players working to develop 15+ pipeline drugs for metastatic Merkel cell carcinoma treatment.

• The leading metastatic Merkel cell carcinoma companies include Incyte Corporation, Transgene, Ocellaris Pharma, Roche, Exelixis, Sensei Biotherapeutics, Checkmate Pharmaceuticals, SOTIO Biotech, and others are evaluating their lead assets to improve the metastatic Merkel cell carcinoma treatment landscape.

• Key metastatic Merkel cell carcinoma pipeline therapies in various stages of development include Retifanlimab, BT-001, OC-001, Nivolumab, Cabozantinib, SNS 401 NG, Vidutolimod, SO-C101, and others.

• In July 2025, the PANDORA Phase II trial design was published (first-line chemo-immunotherapy in advanced MCC). Primary endpoint: overall response rate; secondary: OS, PFS, QoL; includes immune/genomic correlative work.

• In June 2025, the FDA removes partial clinical hold on TuHURA’s Phase 3 IFx-2.0 trial (frontline with pembrolizumab). The manufacturing-related hold was lifted; the accelerated-approval study in advanced/metastatic MCC proceeds under a Special Protocol Assessment.

• In March 2025, an update was provided on retifanlimab-dlwr (Zynyz) for metastatic Merkel cell carcinoma (mMCC), including a recap and expert discussion following its FDA accelerated approval on March 22, 2023. The approval was based on efficacy and safety data from the POD1UM-201 trial, supporting its use in patients with metastatic or recurrent locally advanced MCC.

 

Metastatic Merkel Cell Carcinoma Overview

Metastatic Merkel Cell Carcinoma (mMCC) is a rare but aggressive form of skin cancer that originates in Merkel cells, which are found at the base of the epidermis. It is most often caused by either infection with Merkel cell polyomavirus (MCPyV) or extensive ultraviolet (UV) exposure. The cancer typically affects older adults and individuals with weakened immune systems. mMCC is characterized by rapid growth and a high likelihood of spreading (metastasizing) to lymph nodes and distant organs, often leading to poor prognosis if not detected and treated early.

Due to its aggressive nature, treatment of mMCC requires a multidisciplinary approach. Immunotherapy has become a cornerstone of treatment, particularly immune checkpoint inhibitors like retifanlimab and nivolumab, which help restore the immune system’s ability to recognize and destroy cancer cells. Chemotherapy, radiation, and surgery may also be used depending on disease stage and patient condition. Ongoing clinical trials are exploring novel therapies such as oncolytic viruses, cancer vaccines, and targeted agents to improve outcomes in advanced cases.

Find out more about metastatic Merkel cell carcinoma medication at https://www.delveinsight.com/report-store/metastatic-merkel-cell-carcinoma-pipeline-insight

 

Metastatic Merkel Cell Carcinoma Treatment Analysis: Drug Profile

Retifanlimab: Incyte

Retifanlimab (formerly INCMGA0012) is an investigational intravenous PD-1 inhibitor currently being studied in registration-directed clinical trials. It is being evaluated as a monotherapy for the treatment of microsatellite instability-high endometrial cancer, Merkel cell carcinoma, and squamous cell carcinoma of the anal canal (SCAC). Additionally, it is being tested in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.

Learn more about the novel and emerging metastatic Merkel cell carcinoma pipeline therapies.

 

Metastatic Merkel Cell Carcinoma Therapeutics Assessment

By Product Type

• Mono

• Combination

• Mono/Combination.

 

By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

By Route of Administration

• Oral

• Intravenous

• Subcutaneous

 

By Molecule Type

• Small molecule

• Cell Therapy

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Scope of the Metastatic Merkel Cell Carcinoma Pipeline Report

• Coverage: Global

• Key Metastatic Merkel Cell Carcinoma Companies: Incyte Corporation, Transgene, Ocellaris Pharma, Roche, Exelixis, Sensei Biotherapeutics, Checkmate Pharmaceuticals, SOTIO Biotech, and others.

• Key Metastatic Merkel Cell Carcinoma Pipeline Therapies: Retifanlimab, BT-001, OC-001, Nivolumab, Cabozantinib, SNS 401 NG, Vidutolimod, SO-C101, and others.

Explore detailed insights on drugs used in the treatment of Metastatic Merkel Cell Carcinoma here.

 

Table of Contents

1. Introduction

2. Executive Summary

3. Metastatic Merkel Cell Carcinoma Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Metastatic Merkel Cell Carcinoma Pipeline Therapeutics

6. Metastatic Merkel Cell Carcinoma Pipeline: Late-Stage Products (Phase III)

7. Metastatic Merkel Cell Carcinoma Pipeline: Mid-Stage Products (Phase II)

8. Metastatic Merkel Cell Carcinoma Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Merkel Cell Carcinoma Pipeline Insight 2025: Immunotherapies, Targeted Agents, and Novel Biologics Reshape the Treatment Landscape | DelveInsight

Insulin Resistance Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | Exscien Corp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics BV

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Insulin Resistance Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.

 

The Insulin Resistance Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Insulin Resistance Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Insulin Resistance treatment therapies with a considerable amount of success over the years.

  • Insulin Resistance companies working in the treatment market are Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others, are developing therapies for the Insulin Resistance treatment

  • Emerging Insulin Resistance therapies in the different phases of clinical trials are- CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others are expected to have a significant impact on the Insulin Resistance market in the coming years.

  • In May 2025, A study published in *Nature* titled, “Acute regulation of murine adipose tissue lipolysis and insulin resistance by the TGFβ superfamily protein GDF3,” explored the role of Growth Differentiation Factor 3 (GDF3) in mature adipocyte function. The research revealed that inducible loss of GDF3 activity in obese adult mice resulted in decreased lipolysis, enhanced glucose tolerance, and reduced fluctuations in blood glucose levels.

  • In June 2024, OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related metabolic disorders, announced new findings on its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of the American Diabetes Association. The company shared three abstracts highlighting data that demonstrate the safety and early efficacy of TLC-6740 in healthy volunteers, along with preclinical results showing weight reduction through enhanced energy expenditure and improved glycemic control in mouse models. These benefits were observed with TLC-6740 as a standalone treatment and in combination with the selective ACC2 inhibitor TLC-3595 and a GLP-1 receptor agonist.

 

Insulin Resistance Overview

Insulin resistance is a condition in which the body’s cells do not respond effectively to insulin, a hormone that helps move glucose (sugar) from the blood into cells for energy. As a result, the pancreas produces more insulin to compensate, leading to higher insulin levels in the blood. Over time, this can cause elevated blood sugar levels and increase the risk of developing type 2 diabetes, obesity, and cardiovascular diseases.

 

Get a Free Sample PDF Report to know more about Insulin Resistance Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/insulin-resistance-pipeline-insight

 

Emerging Insulin Resistance Drugs Under Different Phases of Clinical Development Include:

  • CRB-913: Corbus Pharmaceuticals Holdings, Inc.

  • Ziftomenib: Kura Oncology, Inc

  • SCO-240: SCOHIA Pharma Inc

  • ATR-258: Atrogi

  • ID110521156: YUNOVIA CO.,LTD.

  • Visepegenatide (PB-119): PegBio

  • Retatrutide: Eli Lilly and Company

  • TNX-1900: Tonix Pharmaceuticals

  • Steglatro: Pfizer

  • TLC-3595: OrsoBio

  • Ladarixin: Dompe Farmaceutici

  • Avandia: GlaxoSmithKline

  • Triflusal (DCI): J. Uriach and Company

  • MICARDIS® (telmisartan): Boehringer Ingelheim

  • U-500 insulin: Eli Lilly and Company

  • Vildagliptin: Novartis

  • GFT505: Genfit

  • Nateglinide: Novartis

  • Olmesartan medoxomil: Daiichi Sankyo, Inc.

 

Insulin Resistance Route of Administration

Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous

 

Insulin Resistance Molecule Type

Insulin Resistance Products have been categorized under various Molecule types, such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Insulin Resistance Pipeline Therapeutics Assessment

  • Insulin Resistance Assessment by Product Type

  • Insulin Resistance By Stage and Product Type

  • Insulin Resistance Assessment by Route of Administration

  • Insulin Resistance By Stage and Route of Administration

  • Insulin Resistance Assessment by Molecule Type

  • Insulin Resistance by Stage and Molecule Type

 

DelveInsight’s Insulin Resistance Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Insulin Resistance product details are provided in the report. Download the Insulin Resistance pipeline report to learn more about the emerging Insulin Resistance therapies

 

Some of the key companies in the Insulin Resistance Therapeutics Market include:

Key companies developing therapies for Insulin Resistance are – Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, Trigemina Inc, and others.

 

Insulin Resistance Pipeline Analysis:

The Insulin Resistance pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Insulin Resistance with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Insulin Resistance Treatment.

  • Insulin Resistance key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Insulin Resistance Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Insulin Resistance market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Insulin Resistance drugs and therapies

 

Insulin Resistance Pipeline Market Drivers

  • Increasing prevalence of chronic diseases, particularly diabetes, government initiatives to motivate research in diabetes, aging population and increasing obesity prevalence in developing countries are some of the important factors that are fueling the Insulin Resistance Market.

 

Insulin Resistance Pipeline Market Barriers

  • However, less clinical information on insulin resistance has restricted the scope of drug development, limited drugs approved by the FDA are available in the market for the treatment of insulin resistance and other factors are creating obstacles in the Insulin Resistance Market growth.

 

Scope of Insulin Resistance Pipeline Drug Insight

  • Coverage: Global

  • Key Insulin Resistance Companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others

  • Key Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others

  • Insulin Resistance Therapeutic Assessment: Insulin Resistance current marketed and Insulin Resistance emerging therapies

  • Insulin Resistance Market Dynamics: Insulin Resistance market drivers and Insulin Resistance market barriers

 

Request for Sample PDF Report for Insulin Resistance Pipeline Assessment and clinical trials

 

Table of Contents

1. Insulin Resistance Report Introduction

2. Insulin Resistance Executive Summary

3. Insulin Resistance Overview

4. Insulin Resistance- Analytical Perspective In-depth Commercial Assessment

5. Insulin Resistance Pipeline Therapeutics

6. Insulin Resistance Late Stage Products (Phase II/III)

7. Insulin Resistance Mid Stage Products (Phase II)

8. Insulin Resistance Early Stage Products (Phase I)

9. Insulin Resistance Preclinical Stage Products

10. Insulin Resistance Therapeutics Assessment

11. Insulin Resistance Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Insulin Resistance Key Companies

14. Insulin Resistance Key Products

15. Insulin Resistance Unmet Needs

16 . Insulin Resistance Market Drivers and Barriers

17. Insulin Resistance Future Perspectives and Conclusion

18. Insulin Resistance Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insulin Resistance Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | Exscien Corp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics BV

Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma, Takeda

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Myasthenia Gravis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.

 

Some of the key takeaways from the Myasthenia Gravis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.

  • Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment

  • Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years.

  • In May 2025, The FDA approved a new therapy for generalized myasthenia gravis (gMG), a condition characterized by severe muscle weakness, rapid fatigue, and challenges with speech and swallowing. This new treatment, called nipocalimab and marketed as Imaavy, provides a long-lasting option for symptom management, benefiting approximately 100,000 people affected by gMG in the U.S. It is the first and only therapy designed to address the underlying cause of the disease in adults and adolescents aged 12 and older who possess specific antibodies associated with gMG.

  • In April 2025, Nipocalimab-aahu is a human IgG1 monoclonal antibody designed to target the neonatal Fc receptor (FcRn) with high affinity, thereby reducing circulating IgG levels. Its approval was supported by results from the Phase 3 Vivacity-MG3 trial (ClinicalTrials.gov ID: NCT04951622), a randomized, double-blind, placebo-controlled study. The trial involved adult patients with generalized myasthenia gravis (gMG), classified as class II to IV by the Myasthenia Gravis Foundation of America, who had an inadequate response to standard therapies, indicated by an MG-ADL score of 6 or above.

  • In April 2025, Promising results from the Phase 3 clinical trial (NCT05737160) assessing the safety and efficacy of Telitacicept (RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were shared during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting.

  • In April 2025, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotech company focused on developing cell therapies for autoimmune disorders, has reported 12-month efficacy and safety results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Patients who received a single six-week treatment course of Descartes-08 showed sustained improvement in MG symptoms, which persisted through the 12-month follow-up evaluation.

  • In March 2025, Immunovant decided not to pursue regulatory approval for its myasthenia gravis (MG) treatment, batoclimab, despite the Phase III study meeting its primary endpoint of reducing disease symptoms. Instead, the company will leverage the data to further develop its alternative therapy, IMVT-1402. The Phase III randomized trial (NCT05403541) assessed the impact of weekly or bi-monthly doses of batoclimab on acetylcholine receptor antibody-positive (AChR+) patients, using the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over a 12-week period.

  • In December 2024, Cartesian Therapeutics revealed updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate, Descartes-08, for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The double-blind, placebo-controlled, crossover trial (NCT06038474) was open-label and involved 36 heavily pre-treated, symptomatic patients. Half of the participants received a placebo, while the other half were treated with Descartes-08, both administered as six weekly outpatient infusions without prior chemotherapy preconditioning.

 

Myasthenia Gravis Overview

Myasthenia Gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to “grave muscle weakness,” reflects the primary symptom of the condition. Myasthenia Gravis occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles.

 

Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight

 

Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include:

  • Povetacicept: Alpine Immune Science

  • TOL 2: Toleranzia

  • MuSK-CAART: Cabaletta Bio

  • RLYB116: Rallybio

  • ALXN2050: Alexion Pharmaceuticals

  • TAK-079: Takeda

  • Descartes-08: Cartesian Therapeutics

  • Telitacicept: RemeGen

  • Inebilizumab: Horizon Therapeutics

 

Myasthenia Gravis Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Molecule Type

 

Myasthenia Gravis Molecule Type

Myasthenia Gravis Products have been categorized under various Molecule types, such as

  • Vaccines

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Product Type

 

Myasthenia Gravis Pipeline Therapeutics Assessment

  • Myasthenia Gravis Assessment by Product Type

  • Myasthenia Gravis By Stage and Product Type

  • Myasthenia Gravis Assessment by Route of Administration

  • Myasthenia Gravis By Stage and Route of Administration

  • Myasthenia Gravis Assessment by Molecule Type

  • Myasthenia Gravis by Stage and Molecule Type

 

DelveInsight’s Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies

 

Some of the key companies in the Myasthenia Gravis Therapeutics Market include:

Key companies developing therapies for Myasthenia Gravis are – CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others.

 

Myasthenia Gravis Pipeline Analysis:

The Myasthenia Gravis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.

  • Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies

 

Myasthenia Gravis Pipeline Market Drivers

  • Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market.

 

Myasthenia Gravis Pipeline Market Barriers

  • However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth.

 

Scope of Myasthenia Gravis Pipeline Drug Insight

  • Coverage: Global

  • Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others

  • Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others

  • Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies

  • Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers

 

Request for Sample PDF Report for Myasthenia Gravis Pipeline Assessment and clinical trials

 

Table of Contents

1. Myasthenia Gravis Report Introduction

2. Myasthenia Gravis Executive Summary

3. Myasthenia Gravis Overview

4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment

5. Myasthenia Gravis Pipeline Therapeutics

6. Myasthenia Gravis Late Stage Products (Phase II/III)

7. Myasthenia Gravis Mid Stage Products (Phase II)

8. Myasthenia Gravis Early Stage Products (Phase I)

9. Myasthenia Gravis Preclinical Stage Products

10. Myasthenia Gravis Therapeutics Assessment

11. Myasthenia Gravis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myasthenia Gravis Key Companies

14. Myasthenia Gravis Key Products

15. Myasthenia Gravis Unmet Needs

16 . Myasthenia Gravis Market Drivers and Barriers

17. Myasthenia Gravis Future Perspectives and Conclusion

18. Myasthenia Gravis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma, Takeda

Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris

The Key Night Vision Disturbances Companies in the market inlcudee – Ocuphire Pharma/Viatris, and others.

 

DelveInsight’s “Night Vision Disturbances Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Night Vision Disturbances, historical and forecasted epidemiology as well as the Night Vision Disturbances market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Night Vision Disturbances, offering comprehensive insights into the Night Vision Disturbances revenue trends, prevalence, and treatment landscape. The report delves into key Night Vision Disturbances statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Night Vision Disturbances therapies. Additionally, we cover the landscape of Night Vision Disturbances clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Night Vision Disturbances treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Night Vision Disturbances space.

 

To Know in detail about the Night Vision Disturbances market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Night Vision Disturbances Market Forecast

 

Some of the key facts of the Night Vision Disturbances Market Report:

  • The Night Vision Disturbances market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In June 2025, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company advancing gene therapies for inherited retinal diseases (IRDs) and small molecule treatments for other eye disorders, announced positive topline results from LYNX-2, its pivotal Phase 3 trial. The study evaluated Phentolamine Ophthalmic Solution 0.75% for addressing significant, chronic night driving difficulties in keratorefractive patients with impaired mesopic vision.

  • In February 2025, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotech company focused on developing gene therapies for inherited retinal diseases (IRDs) and other eye disorders, has announced the completion of patient enrollment in the VEGA-3 Phase 3 clinical trial of Phentolamine Ophthalmic Solution 0.75% for treating presbyopia. Additionally, the company reported that enrollment in the LYNX-2 pivotal Phase 3 trial—targeting visual loss in low light conditions following keratorefractive surgery—is progressing well, with enrollment expected to be completed in the first half of 2025.

  • In September 2024, Johnson & Johnson, a global leader in eye care, announced the expanded U.S. launch of its latest presbyopia-correcting intraocular lens (PC-IOL), TECNIS Odyssey. This innovative IOL delivers an unparalleled continuous range of vision, allowing patients to see clearly from far to near and intermediate distances, significantly reducing the need for glasses. Built on the TECNIS platform, TECNIS Odyssey offers double the contrast in low-light conditions compared to PanOptix. Additionally, patients with TECNIS Odyssey IOL can read 14% smaller print on average than those with PanOptix IOL, and 93% reported no or mild visual disturbances such as halos, glare, or starbursts one month post-surgery.

  • In January 2024, Ocuphire Pharma secured US FDA Agreement under an SPA, leading to the initiation of the LYNX-2 Phase III trial in April 2024 to evaluate Phentolamine Ophthalmic Solution for improving night vision post-refractive surgery.

  • In 2023, the Night Vision Disturbance (NVD) market, including supportive care, was valued at USD 3,216 million across the 7MM. The market is anticipated to grow with the expected introduction of emerging therapies during the forecast period (2024–2034).

  • In 2023, the US held the largest market size for Night Vision Disturbance (NVD) among the 7MM, with an estimated USD 1,754 million. This market is expected to grow at a CAGR of 1.08% through 2034.

  • In 2023, Germany had the largest market size for Night Vision Disturbance (NVD) among EU countries, with nearly USD 283 million, while Spain had the smallest market size, at approximately USD 149 million.

  • In 2023, the market size for Night Vision Disturbance (NVD) in Japan was estimated to be approximately USD 434 million.

  • Key Night Vision Disturbances Companies: Ocuphire Pharma/Viatris, and others

  • Key Night Vision Disturbances Therapies: Phentolamine Ophthalmic Solution 0.75% (Nyxol), and others

  • The Night Vision Disturbances market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Night Vision Disturbances pipeline products will significantly revolutionize the Night Vision Disturbances market dynamics.

  • DelveInsight’s assessment estimated that the total diagnosed prevalent cases of Night Vision Disturbance (NVD) across the 7MM reached nearly 55 million in 2023.

  • In 2023, the US accounted for the largest share of total diagnosed prevalent cases of Night Vision Disturbance (NVD), representing 44%, and this number is expected to increase in the future.

  • In 2023, Germany reported the highest number of diagnosed prevalent cases of Night Vision Disturbance (NVD) among European countries, with around 6 million cases, followed by France with approximately 4 million cases. Spain had the lowest prevalence, with about 3 million cases.

  • In 2023, Japan reported nearly 9 million diagnosed prevalent cases of Night Vision Disturbance (NVD), representing about 16% of the total cases across the 7MM.

 

Night Vision Disturbances Overview

Night Vision Disturbance refers to difficulties or impairments in seeing clearly in low-light or nighttime conditions. This condition can be caused by various factors, including aging, underlying health issues such as cataracts, retinal diseases, or conditions like vitamin A deficiency. Individuals with NVD often experience reduced visual acuity, glare, halos, or difficulty adjusting to darkness, which can impact daily activities such as driving at night or navigating low-light environments. Treatment and management typically focus on addressing the underlying causes of the disturbance.

 

Get a Free sample for the Night Vision Disturbances Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/night-vision-disturbances-market

 

Night Vision Disturbances Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Night Vision Disturbances Epidemiology Segmentation:

The Night Vision Disturbances market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Night Vision Disturbances

  • Prevalent Cases of Night Vision Disturbances by severity

  • Gender-specific Prevalence of Night Vision Disturbances

  • Diagnosed Cases of Episodic and Chronic Night Vision Disturbances

 

Download the report to understand which factors are driving Night Vision Disturbances epidemiology trends @ Night Vision Disturbances Epidemiology Forecast

 

Night Vision Disturbances Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Night Vision Disturbances market or expected to get launched during the study period. The analysis covers Night Vision Disturbances market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Night Vision Disturbances Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Night Vision Disturbances Therapies and Key Companies

  • Phentolamine Ophthalmic Solution 0.75% (Nyxol): Ocuphire Pharma/Viatris

 

Discover more about therapies set to grab major Night Vision Disturbances market share @ Night Vision Disturbances Treatment Landscape

 

Night Vision Disturbances Market Drivers

  • Aging Population

  • Growing Awareness

  • Technological Advancements

  • Increased Research & Development

  • Rising Prevalence of Retinal Diseases

  • Emerging Therapies

 

Night Vision Disturbances Market Barriers

  • High Treatment Costs

  • Limited Awareness in Rural Areas

  • Availability of Standardized Treatment

  • Slow Adoption of New Therapies

  • Complex Regulatory Approvals

 

Scope of the Night Vision Disturbances Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Night Vision Disturbances Companies: Phentolamine Ophthalmic Solution 0.75% (Nyxol), and others

  • Key Night Vision Disturbances Therapies: Ocuphire Pharma/Viatris, and others

  • Night Vision Disturbances Therapeutic Assessment: Night Vision Disturbances current marketed and Night Vision Disturbances emerging therapies

  • Night Vision Disturbances Market Dynamics: Night Vision Disturbances market drivers and Night Vision Disturbances market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Night Vision Disturbances Unmet Needs, KOL’s views, Analyst’s views, Night Vision Disturbances Market Access and Reimbursement

 

To know more about Night Vision Disturbances companies working in the treatment market, visit @ Night Vision Disturbances Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Night Vision Disturbances Market Report Introduction

2. Executive Summary for Night Vision Disturbances

3. SWOT analysis of Night Vision Disturbances

4. Night Vision Disturbances Patient Share (%) Overview at a Glance

5. Night Vision Disturbances Market Overview at a Glance

6. Night Vision Disturbances Disease Background and Overview

7. Night Vision Disturbances Epidemiology and Patient Population

8. Country-Specific Patient Population of Night Vision Disturbances

9. Night Vision Disturbances Current Treatment and Medical Practices

10. Night Vision Disturbances Unmet Needs

11. Night Vision Disturbances Emerging Therapies

12. Night Vision Disturbances Market Outlook

13. Country-Wise Night Vision Disturbances Market Analysis (2020–2034)

14. Night Vision Disturbances Market Access and Reimbursement of Therapies

15. Night Vision Disturbances Market Drivers

16. Night Vision Disturbances Market Barriers

17. Night Vision Disturbances Appendix

18. Night Vision Disturbances Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris

Acquired Hemophilia A Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acquired Hemophilia A pipeline constitutes 10+ key companies continuously working towards developing 10+ Acquired Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Acquired Hemophilia A Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acquired Hemophilia A Market.

 

The Acquired Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Acquired Hemophilia A Pipeline Report

  • Companies across the globe are diligently working toward developing novel Acquired Hemophilia A treatment therapies with a considerable amount of success over the years. Acquired Hemophilia A Key players such as – Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Acquired Hemophilia A treatment

  • Acquired Hemophilia A Emerging therapies such as – BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Acquired Hemophilia A market in the coming years.

  • In June 2025, According to a study published in Leukemia titled “Anti-CD19 CAR-T cell therapy for acquired hemophilia A,” CAR T-cell therapy—an immune-based treatment initially developed for cancer—has, for the first time, been successfully used to treat a patient with acquired hemophilia A (AHA). Hemophilia A is characterized by a deficiency or dysfunction of factor VIII (FVIII), a key clotting protein. This deficiency increases the risk of severe and prolonged bleeding episodes. The condition arises from genetic mutations affecting the gene responsible for producing FVIII.

  • In February 2025, Researchers have documented two cases where factor VIII inhibitors were successfully eliminated in patients with acquired hemophilia A treated with rituximab. Published in Hematology, these reports highlighted rituximab as both safe and effective, potentially serving as a first-line therapy for acquired hemophilia A. The authors explained, “Rituximab, a monoclonal antibody targeting CD20-positive B cells, shows promise in treating acquired hemophilia by decreasing the production of autoantibodies against factor VIII.” They also noted that current guidelines recommend rituximab as a first-line option primarily for patients with poor prognosis or those who cannot tolerate standard first-line treatments.

  • In July 2024, Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced Pfizer Inc.’s positive topline results from the Phase 3 AFFINE trial (NCT04370054). The study evaluates giroctocogene fitelparvovec, an investigational gene therapy co-developed by Sangamo and licensed to Pfizer for treating adults with moderately severe to severe hemophilia A.

  • In May 2024, Danish pharmaceutical firm Novo Nordisk announced key findings from FRONTIER II, a Phase IIIa study evaluating subcutaneous Mim8 for haemophilia A treatment.

 

Acquired Hemophilia A Overview

Acquired Hemophilia A is a rare autoimmune bleeding disorder in which the body produces antibodies (autoantibodies) that attack clotting factor VIII, a protein essential for blood clotting. Unlike congenital hemophilia, it develops later in life and is not inherited. This condition can lead to spontaneous, severe bleeding into the skin, muscles, or internal organs, even in individuals with no prior history of bleeding disorders. It is often associated with other conditions such as autoimmune diseases, cancer, or pregnancy, but can also occur without a known cause. Prompt diagnosis and treatment are essential to manage bleeding and control the immune response.

 

To know more about the Acquired Hemophilia A pipeline report, click here:

https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight

 

Acquired Hemophilia A Pipeline Therapies along with Key Players:

  • BBM-H901: Belief Biomed

  • ISU304: ISU ABXIS

  • TU7710: TiumBio

  • BE-101: Be Biopharma

  • REGV131: Regeneron Pharmaceuticals

  • PF-06838435: Pfizer

  • ANB-002: Biocad

  • AAV5-hFIXco-Padua: CSL Behring

  • VGB-R04: Shanghai Vitalgen BioPharma

  • AskBio009: Baxalta

  • AMA005: Amarna therapeutics

  • CB 2679d-GT: Catalyst Biosciences

  • FLT180a: Freeline Therapeutics

  • BBM-H901: Belief BioMed

  • SerpinPC: Centessa Pharmaceuticals

  • Concizumab: Novo Nordisk

  • Fitusiran: Sanofi

  • PF-06741086: Pfizer

 

Acquired Hemophilia A Pipeline Therapeutics Assessment

TheAcquired Hemophilia A Pipeline report proffers an integral view of the Acquired Hemophilia A emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Acquired Hemophilia A Pipeline Clinical Phases:

DelveInsight’s Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Further Acquired Hemophilia A product details are provided in the report. Download the Acquired Hemophilia A pipeline report to learn more about the emerging Acquired Hemophilia A therapies

 

Some of the key companies in the Acquired Hemophilia A Therapeutics Market include:

Key companies developing therapies for Acquired Hemophilia A treatment are – Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

 

Acquired Hemophilia A Pipeline Analysis:

The report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the Acquired Hemophilia A treatment with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acquired Hemophilia A Treatment.

  • Acquired Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Acquired Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acquired Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Acquired Hemophilia A Pipeline Market Drivers

  • Increasing prevalence of Acquired Hemophilia A disease

  • Increasing R&D on identifying new therapeutic agents

 

Acquired Hemophilia A Pipeline Market Barriers

  • High cost of Acquired Hemophilia A treatment

 

Scope of Acquired Hemophilia A Pipeline Drug Insight

  • Coverage: Global

  • Key Acquired Hemophilia A Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others

  • Key Acquired Hemophilia A Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others

  • Acquired Hemophilia A Therapeutic Assessment: Acquired Hemophilia A current marketed and Acquired Hemophilia A emerging therapies

  • Acquired Hemophilia A Market Dynamics: Acquired Hemophilia A market drivers and Acquired Hemophilia A market barriers

 

Get a Free Sample PDF Report to know more about Acquired Hemophilia A Pipeline Assessment

 

Table of Contents

1

Acquired Hemophilia A Report Introduction

2

Acquired Hemophilia A Executive Summary

3

Acquired Hemophilia A Overview

4

Acquired Hemophilia A- Analytical Perspective In-depth Commercial Assessment

5

Acquired Hemophilia A Pipeline Therapeutics

6

Acquired Hemophilia A Late Stage Products (Phase II/III)

7

Acquired Hemophilia A Mid Stage Products (Phase II)

8

Acquired Hemophilia A Early Stage Products (Phase I)

9

Acquired Hemophilia A Preclinical Stage Products

10

Acquired Hemophilia A Therapeutics Assessment

11

Acquired Hemophilia A Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Acquired Hemophilia A Key Companies

14

Acquired Hemophilia A Key Products

15

Acquired Hemophilia A Unmet Needs

16

Acquired Hemophilia A Market Drivers and Barriers

17

Acquired Hemophilia A Future Perspectives and Conclusion

18

Acquired Hemophilia A Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acquired Hemophilia A Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

Epilepsy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma

The Key Epilepsy Companies in the market include – Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others.

 

DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast

 

Some of the key facts of the Epilepsy Market Report:

  • The Epilepsy market size was valued ~USD 9 billion in 2023 and is anticipated to grow with a significant CAGR of 7% during the study period (2020-2034)

  • In May 2025, Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision therapies for neurological and psychiatric conditions, announced its financial results for the first quarter ending March 31, 2025, along with a business update. The company described 2025 as a pivotal year, as it moves toward presenting initial proof-of-concept data for RAP-219 from its Phase 2a trial in patients with refractory focal epilepsy and advances its pipeline-in-a-product approach by launching a clinical trial for bipolar mania.

  • In April 2025, In a Phase Ib/IIa trial, Lundbeck’s receptor superagonist, developed to treat seizures linked to developmental and epileptic encephalopathies (DEEs), demonstrated a 61.2% reduction in total seizures. Interim data from the open-label extension (OLE) of the Pacific trial (NCT05364021), which evaluated bexicaserin, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, in patients previously on placebo, revealed a 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures in those who had switched from placebo.

  • In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.

  • In November 2024, uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on developing treatments for severe medical conditions, has announced that the first patient has been administered AMT-260 in the GenTLE Phase I/IIa clinical trial for refractory mesial temporal lobe epilepsy (MTLE).

  • In September 2024, Synergia Medical successfully implanted its neurostimulation technology in the first two patients participating in a study aimed at treating epilepsy. These procedures are part of a first-in-human trial being conducted at two locations in Belgium and one in Germany. The surgeries for the initial patients were performed earlier this month at the Belgian sites, according to the company.

  • In 2023, the Epilepsy Treatment Market in the US was valued at around USD 4.3 billion, representing approximately 48% of the total market revenue across the 7MM.

  • In 2023, the Epilepsy Treatment Market in the EU4 and the UK held a market share of approximately 29%. Among these countries, Germany had the largest market share, followed by France and the UK. These figures are expected to evolve during the forecast period.

  • In 2023, the Epilepsy Treatment Market Size in Japan was estimated to be around USD 2.1 billion.

  • In 2023, the total diagnosed prevalent cases of epilepsy in the 7MM were approximately 7 million, with an expected compound annual growth rate (CAGR) of 0.4% through 2034.

  • In 2023, the US had around 3.3 million total diagnosed epilepsy cases, with 14% of them in children and 86% in adults. The total number of epilepsy cases is anticipated to rise by 2034.

  • In 2023, the EU4 and the UK had approximately 1.3 million male cases and 1.5 million female cases of diagnosed epilepsy, with these figures expected to increase over the study period.

  • In 2023, Germany reported the highest number of epilepsy cases among the EU4 and the UK, with approximately 735 thousand cases. Of these, nearly 74% were focal seizures, 18% were generalized seizures, and 8% were classified as other determined or undetermined epileptic seizures.

  • In 2023, Japan had the second-highest number of diagnosed epilepsy cases among the 7MM, with approximately 890 thousand cases. These numbers are anticipated to change over the course of the study period.

  • In Japan, drug-resistant epilepsy/refractory cases accounted for the highest number of epilepsy cases, with approximately 82 thousand in 2023, followed by photosensitivity and childhood absence epilepsy, each with 44 thousand cases. These figures are projected to change by 2034.

  • The epilepsy market is expected to experience steady growth, with a compound annual growth rate (CAGR) of around 7% projected from 2024 to 2034. This growth across the 7MM will be fueled by the launch of new therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others.

  • DelveInsight estimates that in 2023, there were around 7 million total diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% of the cases were in the US, 39% were in the EU4 and the UK, and 13% were in Japan.

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • The Epilepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.

 

Epilepsy Overview

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.

 

Get a Free sample for the Epilepsy Market Report

https://www.delveinsight.com/report-store/epilepsy-market

 

Epilepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Epilepsy

  • Prevalent Cases of Epilepsy by severity

  • Gender-specific Prevalence of Epilepsy

  • Diagnosed Cases of Episodic and Chronic Epilepsy

 

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast

 

Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Epilepsy Therapies and Key Companies

  • LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

  • EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals

  • XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical

  • AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

  • XEN1101/Azetukalner: Xenon Pharmaceuticals

  • Soticlestat (TAK-935): Takeda/Ovid Therapeutics

  • BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences

 

Discover more about therapies set to grab major Epilepsy market share @ Epilepsy Treatment Market

 

Epilepsy Market Strengths

  • Growing Focus On Providing Seizure-Free Life To Fuel Innovations.

  • Growth in The Demand For Epileptic Seizures Treatment

 

Epilepsy Market Opportunities

  • Growing funding for R&D of epilepsy is also contributing as a factor for the market growth.

  • Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market

 

Scope of the Epilepsy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement

 

To know more about Epilepsy companies working in the treatment market, visit @ Epilepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2020–2034)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17. Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma

Car T Cell Therapy For Multiple Myeloma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Car T Cell Therapy For Multiple Myeloma Market.

 

The Car T Cell Therapy For Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Car T Cell Therapy For Multiple Myeloma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Car T Cell Therapy For Multiple Myeloma treatment therapies with a considerable amount of success over the years.

  • Car T Cell Therapy For Multiple Myeloma companies working in the treatment market are Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others, are developing therapies for the Car T Cell Therapy For Multiple Myeloma treatment

  • Emerging Car T Cell Therapy For Multiple Myeloma therapies in the different phases of clinical trials are- Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others are expected to have a significant impact on the Car T Cell Therapy For Multiple Myeloma market in the coming years.

  • In March 2025, Janssen’s CARVYKTI (ciltacabtagene autoleucel) is an autologous T-cell therapy that targets B-cell maturation antigen (BCMA). The treatment works by genetically modifying a patient’s T cells with a transgene encoding a chimeric antigen receptor (CAR), allowing them to detect and destroy BCMA-expressing cells—commonly present in malignant multiple myeloma B-lineage cells, plasma cells, and late-stage B cells. The CAR in CARVYKTI incorporates two single-domain antibodies that tightly bind to human BCMA, boosting T-cell activation, proliferation, and tumor cell destruction. Currently, CARVYKTI is only available to UK patients through clinical trials, as Janssen chose not to seek approval from NICE, keeping it out of NHS use for now. However, access remains possible through ongoing studies.

  • In October 2024, Aurigene Oncology, a unit of Dr. Reddy’s Laboratories, has received approval from the Drugs Controller General of India (DCGI) to begin a Phase 2 clinical trial of Ribrecabtagene autoleucel (DRL-1801), its novel autologous CAR-T cell therapy developed for the treatment of multiple myeloma.

 

Car T Cell Therapy For Multiple Myeloma Overview

CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative and promising form of immunotherapy used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Plasma cells are a crucial part of the immune system responsible for producing antibodies.

 

Get a Free Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight

 

Emerging Car T Cell Therapy For Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:

  • Descartes-11: Cartesian Therapeutics

  • CART-ddBCMA: Arcellx

  • PHE885: Novartis

  • Orvacabtagene Autoleucel: Bristol-Myers Squibb

  • Zevorcabtagene autoleucel (zevor-cel or CT053): CARsgen Therapeutics

  • P-BCMA-ALLO1: Poseida Therapeutics

  • CC-95266: Juno Therapeutics

  • Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A): Nanjing IASO Biotherapeutics

  • CTX120: CRISPR Therapeutics

  • CC-98633: Juno Therapeutics

  • bb21217: bluebird bio

  • UCARTCS1A: Cellectis SA

  • CB-011: Caribou Biosciences

  • LMY-920: Luminary Therapeutics

  • CYAD-211: Celyad Oncology

  • ALLO-715 ± Nirogacestat: Allogene Therapeutics

  • TEG002: Gadeta

  • CAR-T (CAR-GPRC5D): Nanjing IASO Biotherapeutics

 

Car T Cell Therapy For Multiple Myeloma Route of Administration

Car T Cell Therapy For Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Subcutaneous

  • Intravenous

  • Oral

  • Intramuscular

  • Molecule Type

 

Car T Cell Therapy For Multiple Myeloma Molecule Type

Car T Cell Therapy For Multiple Myeloma Products have been categorized under various Molecule types, such as

  • Small molecules

  • Natural metabolites

  • Monoclonal antibodies

  • Product Type

 

Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics Assessment

  • Car T Cell Therapy For Multiple Myeloma Assessment by Product Type

  • Car T Cell Therapy For Multiple Myeloma By Stage and Product Type

  • Car T Cell Therapy For Multiple Myeloma Assessment by Route of Administration

  • Car T Cell Therapy For Multiple Myeloma By Stage and Route of Administration

  • Car T Cell Therapy For Multiple Myeloma Assessment by Molecule Type

  • Car T Cell Therapy For Multiple Myeloma by Stage and Molecule Type

 

DelveInsight’s Car T Cell Therapy For Multiple Myeloma Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Car T Cell Therapy For Multiple Myeloma product details are provided in the report. Download the Car T Cell Therapy For Multiple Myeloma pipeline report to learn more about the emerging Car T Cell Therapy For Multiple Myeloma therapies

 

Some of the key companies in the Car T Cell Therapy For Multiple Myeloma Therapeutics Market include:

Key companies developing therapies for Car T Cell Therapy For Multiple Myeloma are – Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others.

 

Car T Cell Therapy For Multiple Myeloma Pipeline Analysis:

The Car T Cell Therapy For Multiple Myeloma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Car T Cell Therapy For Multiple Myeloma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Car T Cell Therapy For Multiple Myeloma Treatment.

  • Car T Cell Therapy For Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Car T Cell Therapy For Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Car T Cell Therapy For Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma drugs and therapies

 

Car T Cell Therapy For Multiple Myeloma Pipeline Market Drivers

  • Increasing prevalence of Multiple Myeloma, increase in technological advancement of CAR T-cell manufacturing in myeloma are some of the important factors that are fueling the Car T Cell Therapy For Multiple Myeloma Market.

 

Car T Cell Therapy For Multiple Myeloma Pipeline Market Barriers

  • However, high cost associated with the treatment, poor persistence of CAR T cells and other factors are creating obstacles in the Car T Cell Therapy For Multiple Myeloma Market growth.

 

Scope of Car T Cell Therapy For Multiple Myeloma Pipeline Drug Insight

  • Coverage: Global

  • Key Car T Cell Therapy For Multiple Myeloma Companies: Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others

  • Key Car T Cell Therapy For Multiple Myeloma Therapies: Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others

  • Car T Cell Therapy For Multiple Myeloma Therapeutic Assessment: Car T Cell Therapy For Multiple Myeloma current marketed and Car T Cell Therapy For Multiple Myeloma emerging therapies

  • Car T Cell Therapy For Multiple Myeloma Market Dynamics: Car T Cell Therapy For Multiple Myeloma market drivers and Car T Cell Therapy For Multiple Myeloma market barriers

 

Request for Sample PDF Report for Car T Cell Therapy For Multiple Myeloma Pipeline Assessment and clinical trials

 

Table of Contents

1. Car T Cell Therapy For Multiple Myeloma Report Introduction

2. Car T Cell Therapy For Multiple Myeloma Executive Summary

3. Car T Cell Therapy For Multiple Myeloma Overview

4. Car T Cell Therapy For Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment

5. Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics

6. Car T Cell Therapy For Multiple Myeloma Late Stage Products (Phase II/III)

7. Car T Cell Therapy For Multiple Myeloma Mid Stage Products (Phase II)

8. Car T Cell Therapy For Multiple Myeloma Early Stage Products (Phase I)

9. Car T Cell Therapy For Multiple Myeloma Preclinical Stage Products

10. Car T Cell Therapy For Multiple Myeloma Therapeutics Assessment

11. Car T Cell Therapy For Multiple Myeloma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Car T Cell Therapy For Multiple Myeloma Key Companies

14. Car T Cell Therapy For Multiple Myeloma Key Products

15. Car T Cell Therapy For Multiple Myeloma Unmet Needs

16 . Car T Cell Therapy For Multiple Myeloma Market Drivers and Barriers

17. Car T Cell Therapy For Multiple Myeloma Future Perspectives and Conclusion

18. Car T Cell Therapy For Multiple Myeloma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432 +14699457679
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Car T Cell Therapy For Multiple Myeloma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics

Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest Lab

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Idiopathic Constipation pipeline constitutes key companies continuously working towards developing Chronic Idiopathic Constipation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Chronic Idiopathic Constipation Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Idiopathic Constipation Market.

 

The Chronic Idiopathic Constipation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Idiopathic Constipation Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Idiopathic Constipation treatment therapies with a considerable amount of success over the years.

  • Chronic Idiopathic Constipation companies working in the treatment market are ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others, are developing therapies for the Chronic Idiopathic Constipation treatment

  • Emerging Chronic Idiopathic Constipation therapies in the different phases of clinical trials are- LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others are expected to have a significant impact on the Chronic Idiopathic Constipation market in the coming years.

  • In April 2025, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company focused on advancing transformative therapies for gastrointestinal and rare diseases, announced plans to present real-world evidence at the 2025 Digestive Disease Week® (DDW), taking place May 3–6 in San Diego, CA. The presentation will showcase data on the adoption and utilization of newly approved ICD-10 codes in patients with short bowel syndrome (SBS) dependent on parenteral nutrition.

  • In December 2024, NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults, has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its RED (Rectal Expulsion Device). This approval enables NeurAxis to commercially market the device for testing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia, particularly those who are unlikely to see improvement with increased laxative use.

  • In November 2024, Ironwood Pharmaceuticals (Nasdaq: IRWD), a member of the S&P SmallCap 600®, is a leading gastrointestinal (GI) healthcare company dedicated to improving the treatment of GI diseases and setting new standards of care for GI patients. As pioneers in the development of LINZESS® (linaclotide), we are proud to lead the U.S. branded prescription market for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

 

Chronic Idiopathic Constipation Overview

Chronic Idiopathic Constipation is a condition characterized by long-term, unexplained difficulty in passing stool, often accompanied by infrequent bowel movements, straining, and discomfort. The term “idiopathic” indicates that the cause is unknown, as there are no identifiable underlying medical conditions contributing to the constipation. CIC can significantly affect a person’s quality of life and may result in symptoms such as bloating, abdominal pain, and a feeling of incomplete evacuation. It is typically diagnosed when other causes of constipation, such as gastrointestinal disorders or medications, are ruled out. Treatment often involves lifestyle changes, dietary modifications, and medications.

 

Get a Free Sample PDF Report to know more about Chronic Idiopathic Constipation Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-cic-pipeline-insight

 

Emerging Chronic Idiopathic Constipation Drugs Under Different Phases of Clinical Development Include:

  • A3309: Albireo

  • AJG555: EA Pharma Co., Ltd.

  • linaclotide: Astellas Pharma Inc

  • KWA-0711: Kissei Pharmaceutical Co., Ltd.

  • Tegaserod: Novartis

  • TD-5108: Theravance Biopharma

  • YKP10811: SK Life Science, Inc.

  • prucalopride: Movetis

  • KWA-0711: Kissei Pharmaceutical Co., Ltd

  • PEG 4000 (Forlax®): Ipsen

 

Chronic Idiopathic Constipation Pipeline Therapeutics Assessment

  • Chronic Idiopathic Constipation Assessment by Product Type

  • Chronic Idiopathic Constipation By Stage and Product Type

  • Chronic Idiopathic Constipation Assessment by Route of Administration

  • Chronic Idiopathic Constipation By Stage and Route of Administration

  • Chronic Idiopathic Constipation Assessment by Molecule Type

  • Chronic Idiopathic Constipation by Stage and Molecule Type

 

DelveInsight’s Chronic Idiopathic Constipation Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Chronic Idiopathic Constipation product details are provided in the report. Download the Chronic Idiopathic Constipation pipeline report to learn more about the emerging Chronic Idiopathic Constipation therapies

 

Some of the key companies in the Chronic Idiopathic Constipation Therapeutics Market include:

Key companies developing therapies for Chronic Idiopathic Constipation are – Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Abbott, AstraZeneca PLC, Pfizer Inc, Takeda Pharma, and others.

 

Chronic Idiopathic Constipation Pipeline Analysis:

The Chronic Idiopathic Constipation pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Idiopathic Constipation with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Idiopathic Constipation Treatment.

  • Chronic Idiopathic Constipation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Idiopathic Constipation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Idiopathic Constipation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Idiopathic Constipation drugs and therapies

 

Chronic Idiopathic Constipation Pipeline Market Drivers

  • Rising Prevalence of Chronic Idiopathic Constipation, Aging Population, Advancements in Drug Development, Increasing Awareness and Diagnosis Rates, Regulatory Approvals and Pipeline Expansion, Growing Investment in Gastrointestinal Research, are some of the important factors that are fueling the Chronic Idiopathic Constipation Market.

 

Chronic Idiopathic Constipation Pipeline Market Barriers

  • However, High Clinical Trial Failure Rates, Side Effects of Available Treatments, Limited Patient Compliance, High Development Costs, Generic Competition, Regulatory Challenges, and other factors are creating obstacles in the Chronic Idiopathic Constipation Market growth.

 

Scope of Chronic Idiopathic Constipation Pipeline Drug Insight

  • Coverage: Global

  • Key Chronic Idiopathic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others

  • Key Chronic Idiopathic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others

  • bChronic Idiopathic Constipation current marketed and Chronic Idiopathic Constipation emerging therapies

  • Chronic Idiopathic Constipation Market Dynamics: Chronic Idiopathic Constipation market drivers and Chronic Idiopathic Constipation market barriers

 

Request for Sample PDF Report for Chronic Idiopathic Constipation Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Idiopathic Constipation Report Introduction

2. Chronic Idiopathic Constipation Executive Summary

3. Chronic Idiopathic Constipation Overview

4. Chronic Idiopathic Constipation- Analytical Perspective In-depth Commercial Assessment

5. Chronic Idiopathic Constipation Pipeline Therapeutics

6. Chronic Idiopathic Constipation Late Stage Products (Phase II/III)

7. Chronic Idiopathic Constipation Mid Stage Products (Phase II)

8. Chronic Idiopathic Constipation Early Stage Products (Phase I)

9. Chronic Idiopathic Constipation Preclinical Stage Products

10. Chronic Idiopathic Constipation Therapeutics Assessment

11. Chronic Idiopathic Constipation Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Idiopathic Constipation Key Companies

14. Chronic Idiopathic Constipation Key Products

15. Chronic Idiopathic Constipation Unmet Needs

16 . Chronic Idiopathic Constipation Market Drivers and Barriers

17. Chronic Idiopathic Constipation Future Perspectives and Conclusion

18. Chronic Idiopathic Constipation Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest Lab